The Boston Globe to Announce Fourth Annual Tech Power Players 50 List
BOSTON, June 3, 2025 /PRNewswire/ -- The Boston Globe will announce the fourth annual Tech Power Players 50, a list of the most influential, accomplished, and interesting people working across technology in New England, at Tech Innovation Summit on Tuesday, June 10, 2025. A special online edition of the prestigious list will be published the same week, and the list with special features on select honorees will be available in print in Globe Magazine on Sunday, June 15.
This year's list of Tech Power Players honors 50-plus leaders across AI, quantum computing, consumer tech, cybersecurity, health tech, sustainability, and beyond. Eighteen innovators will join the ranks of the region's Tech Power Players for the first time, demonstrating exemplary contributions to the industry and considerable career impact on technology and business in New England.
"Boston continues to be a thriving hub of technology and innovation," said Linda Henry, CEO of Boston Globe Media. "This year's list of Tech Power Players tells a broad story that illustrates the vibrancy of New England's tech industry through the diverse and dynamic achievements of the individuals featured in each sector."
Candidates for this year's list were selected based on the impact of their actions and accomplishments in fostering change and growth across the region. The list is vetted and decided on by the Globe's business and technology team, led by Gregory T. Huang, the Globe's business editor.
"The Globe is proud to recognize the tech leaders whose forward-thinking ideas and energy for change are making a difference in this moment," said Huang. "Our region is at a crossroads in technology, and these leaders are playing a dynamic role in shaping our future success."
In its fourth year, Tech Power Players 50 is a signature project of The Boston Globe's award-winning business and tech journalists. Since 2021, the Globe business and tech team has expanded its coverage to encompass the dynamic and far-reaching influence of The Hub — a region with a distinguished history in tech and an ambitious future in innovation — with offerings that include the Innovation Beat and Trendlines newsletters, profiles of prominent figures in Bold Types, investigations of consumer concerns in The Fine Print, and more.
This year, the Globe's Tech Innovation Summit will also feature the USA-Boston Regional Startup World Cup. Hosted with Pegasus Tech Ventures, the East Coast Regional Pitch Competition will offer an opportunity for Boston's best and brightest to pitch their most innovative startup ideas to qualify for the Grand Finale in Silicon Valley. Learn more about the Tech Innovation Summit and competing in the Startup World Cup.
Read and experience the full Tech Power Players 50 list at Globe.com/tech50 and in a commemorative issue of the Globe Magazine available on June 15.
Contact: Boston Globe Media Communications, 888-729-4091, communications@bostonglobemedia.com
About Boston Globe Media:Boston Globe Media Partners, LLC is a locally owned, award-winning media company serving Boston and New England for over 153 years. Its cornerstone is The Boston Globe, a 27-time Pulitzer Prize-winning news source and one of the most successful metro news organizations in the United States. The Globe is headquartered in Boston with regional bureaus in Washington, D.C., Rhode Island, and New Hampshire. The Globe has been successfully growing its direct subscriber base, today boasting the highest total number of subscribers the organization has had since 2008. The Globe hosts events that connect community members to its journalism and provides a range of digital and home-delivered advertising solutions that reach more consumers than any other New England media brand. Boston Globe Media's portfolio includes The Boston Globe, Globe.com, Boston.com, STAT, The B-Side, Globe Publishing Services, Globe Events, Studio/B, and Boston magazine.
View original content:https://www.prnewswire.com/news-releases/the-boston-globe-to-announce-fourth-annual-tech-power-players-50-list-302470213.html
SOURCE The Boston Globe
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Advanced Ophthalmology Technology Market to Hit Valuation of US$ 16.01 Billion by 2033
The market is rapidly advancing, driven by an aging population's needs. A clear segmentation is emerging hospitals focus on complex, high-margin procedures, while specialized centers increasingly absorb routine surgeries. Chicago, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global advanced ophthalmology technology market was valued at US$ 8.78 billion in 2024 and is expected to reach US$ 16.01 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025–2033. The future of the advanced ophthalmology technology market is being written today in research labs and clinical trials around the world. A robust pipeline of innovative treatments, particularly in areas like gene therapy for inherited and chronic eye diseases, holds the promise of not just managing but potentially reversing vision loss. The intense research activity is also reflected in the continuous stream of new patents being filed, protecting the intellectual property that will form the basis of next-generation devices and therapies. This forward-looking activity, combined with a growing and specialized workforce, ensures a long-term trajectory of growth and transformative breakthroughs for the industry. Download Sample Pages: The scale of innovation is evident in patent and clinical trial data. In 2024 alone, 1,393 international patents related to vision science were published. Ophthalmic Sciences, an innovator in the field, holds 6 total patents, with 3 of those being active globally. The clinical trial landscape is equally vibrant. The RGX-314 gene therapy trial for wet AMD has enrolled 465 patients, while the SOL-R registrational trial for AXPAXLI in the same condition has a target randomization of at least 555 patients. A search on reveals 22 active clinical studies focused on gene therapy for wet AMD. Supporting this innovation is a skilled workforce; the mean number of ophthalmologists per 100,000 inhabitants across Europe is 9.36, with nations like Italy having 12.28 practicing ophthalmology physicians per 100,000 persons in 2024. Niche markets are also showing strong growth, with the U.S. dry eye treatment devices market reaching approximately $99.7 million in 2024 to serve the around 16 million people diagnosed with Dry Eye Disease. Key Findings in Advanced Ophthalmology Technology Market Market Forecast (2033) US$ 16.01 billion CAGR 6.9% Largest Region (2024) North America (39%) By Type Diagnostic (58%) By End Use Hospitals (41%) Top Drivers Rising prevalence of age-related eye diseases boosts technology demand. Continuous technological advancements are improving diagnostic and surgical outcomes. Growing patient awareness regarding the importance of early eye diagnosis. Top Trends Artificial intelligence integration is revolutionizing diagnostics and treatment planning. Increasing surgeon and patient preference for minimally invasive procedures. Shift of routine surgeries from hospitals to specialized outpatient centers. Top Challenges The high acquisition and maintenance costs of advanced ophthalmic technologies. A growing shortage of skilled ophthalmologists to operate new equipment. Complex reimbursement policies and stringent regulatory approval processes. Financial Titans Dominating the Global Advanced Ophthalmology Technology Market Landscape The financial health of key industry players provides a powerful indicator of the market's robust vitality and sustained growth potential. These leading companies are demonstrating exceptional performance through impressive sales figures and strong operational cash flows, reflecting the high demand for their innovative products. Their financial strength not only solidifies their market position but also enables continued investment in the research and development that drives the entire sector forward. A close examination of their financial reports reveals a clear and compelling narrative of a thriving and profitable industry, setting a confident tone for future expansion and shareholder value in a competitive environment. Alcon, a global leader in the advanced ophthalmology technology market, showcases remarkable financial strength, reporting total net sales of $9.8 billion for the full year 2024. The performance was robust across its divisions, with Surgical net sales reaching $5.5 billion and Vision Care net sales hitting $4.3 billion. The company achieved a record cash from operations of $2.1 billion and a record free cash flow of $1.6 billion. A breakdown of 2024 quarterly performance further illustrates this momentum: Q1 sales were $2.4 billion, with $341 million in cash from operations and $229 million in free cash flow. Q2 sales increased to $2.5 billion, with Surgical net sales at $1.4 billion and Vision Care sales reaching $2.2 billion in the first half. Q3 saw net sales of $2.4 billion, with the Surgical segment contributing $1.34 billion, and Q4 sales were $2.5 billion. Bausch + Lomb also posted strong full-year 2024 revenues of $4.791 billion, with its Surgical segment accounting for $843 million and generating $232 million in cash flow from operations for the year. The company's third quarter revenue was $1.196 billion, with the surgical segment at $206 million and cash flow from operations at $154 million, while Q4 surgical revenue was $231 million. Topcon's Eye Care business reported first-half fiscal year 2024 sales of ¥37.1 billion (€224 million), with a full-year revenue forecast of ¥82.0 billion (€495 million). The combined North American and European half-year sales for Topcon were approximately ¥60 billion, underscoring the strong international demand within the advanced ophthalmology technology market. Unprecedented Surgical Volumes Propel Growth in the Advanced Ophthalmology Technology Market The sheer volume of surgical procedures performed worldwide is a primary engine powering the expansion of the market. An aging global population and the increased prevalence of conditions like cataracts are driving millions of patients to seek surgical solutions. Simultaneously, the introduction of safer, faster, and more effective minimally invasive techniques has broadened patient acceptance and accessibility. The statistics on cataract, LASIK, and SMILE procedures paint a vivid picture of a sector experiencing immense procedural demand. Such high volumes necessitate a continuous supply of advanced surgical equipment, implants, and consumables, creating a powerful and self-reinforcing cycle of growth and innovation. By 2025, an estimated 28 million cataract surgeries are performed annually across the globe, which translates to roughly 75,000 procedures every single day. The minimally invasive refractive procedure, Small Incision Lenticule Extraction (SMILE), has already surpassed 10 million procedures performed worldwide as of the end of 2024 in the advanced ophthalmology technology market. Since its FDA approval in 2016, an average of more than 1 million people have chosen SMILE each year, a procedure now offered by over 2,000 surgeons in 70 countries. The demand for intraocular lenses (IOLs) is staggering, with a projected 200 million patients requiring IOL implantation by 2025. In the United States alone, approximately 800,000 LASIK procedures are performed annually. Growth is also pronounced in developing markets; the estimated cataract surgery rate in China is expected to reach 350 per 100,000 people by 2025. Illustrating global outreach efforts, one specific aid project in Cambodia has already provided free surgery to 3,138 cataract patients, highlighting the vast unmet need that technology can address. Next-Generation Diagnostic and Monitoring Tools Redefine Patient Care and Market Demand Early and accurate diagnosis is the cornerstone of effective ophthalmology, and advanced diagnostic equipment is at the forefront of advanced ophthalmology technology market. Technologies like Optical Coherence Tomography (OCT) have become indispensable, providing high-resolution, cross-sectional images of the retina that enable the detection and management of numerous sight-threatening diseases. The growing prevalence of conditions such as diabetic retinopathy and age-related macular degeneration (AMD) is directly fueling the demand for these sophisticated diagnostic platforms. The market is responding with increasingly powerful and user-friendly devices, including handheld and automated units, that are expanding access to high-quality care from specialized clinics to primary care settings. The adoption rate of these technologies is reflected in strong sales figures, with 18,700 handheld OCT units sold globally in 2023. The clinical utility is immense, with over 50 million diabetes-related OCT scans performed annually. The technology's application in the advanced ophthalmology technology market is even extending beyond human medicine, with over 500 veterinary OCT devices now in use for animal diagnostics. Industry leader Topcon has sold over 20,000 units of its Maestro OCT system globally as of late 2023, a testament to the device's popularity and reliability. The urgency for such advanced diagnostic capability is underscored by daunting projections; approximately 200 million individuals are expected to be affected by AMD by the year 2040, creating a massive patient population in need of vigilant monitoring. Premium Intraocular Lenses Signal a Paradigm Shift in Cataract Surgery Outcomes The intraocular lens (IOL) segment has evolved far beyond simple vision correction, entering an era of premium technology that offers patients a range of lifestyle-enhancing benefits. Today's advanced IOLs can correct presbyopia, astigmatism, and other refractive errors, often reducing or eliminating a patient's dependence on glasses after cataract surgery. This shift towards premium, high-performance lenses represents a significant value-add in the cataract surgery space, driving revenue growth and patient satisfaction. As patient expectations rise, so does the demand for technologies that deliver superior visual outcomes, making the premium IOL sector a key growth area within the advanced ophthalmology technology market. The market's scale is substantial, with annual IOL lens unit shipments reaching 42 million in 2023, corresponding with the roughly 25 million cataract surgeries performed that year. The procedural efficiency in modern clinics further fuels this demand. High-volume cataract clinics now see surgeons implanting an average of 1,200 lenses per year. At an institutional level, surgical centers are now performing an average of 4,500 cataract cases annually. These high procedural volumes, combined with the increasing adoption of premium IOL technologies, create a powerful economic engine that supports ongoing innovation in lens design, materials, and functionality. Robust Investment and Venture Capital Fueling Future Ophthalmic Technology Market Breakthroughs A vibrant ecosystem of investment is crucial for nurturing the next wave of innovation, and the ophthalmology sector is attracting significant capital from diverse sources. Major corporations in the advanced ophthalmology technology market are channeling billions into research and development, while a dynamic venture capital landscape is providing essential funding for startups and emerging technologies. This influx of capital is accelerating the development of groundbreaking therapies, more advanced surgical devices, and sophisticated software platforms. The high level of merger and acquisition activity further signals a mature and attractive market where proven innovations are being rapidly integrated into larger commercial platforms, promising a future rich with transformative solutions. The financial commitment to innovation is clear. Alcon's R&D investment for the twelve months ending March 31, 2025, stood at an impressive $899 million, with annual R&D expenses for 2024 totaling $876 million. Across the industry, total investment in ophthalmology in 2024 exceeded $6.3 billion. The market also saw 18 merger and acquisition transactions in 2024, indicating strong consolidation and strategic growth activity. The venture capital pipeline is equally robust, with financing in ophthalmology for the first quarter of 2025 reaching $515.7 million across 21 transactions. As of May 2025, U.S. ophthalmology companies had already raised $597 million in equity funding through 15 rounds. Looking at a longer trend, the total venture capital investment in the ophthalmic devices sector over the last 10 years has amounted to a formidable $2.51 billion. Artificial Intelligence Integration Revolutionizes Diagnostics in the Advanced Ophthalmology Technology Market Artificial intelligence (AI) is rapidly transitioning from a theoretical concept to a practical and powerful clinical tool within the market. AI algorithms are now capable of analyzing retinal images with remarkable speed and accuracy, detecting early signs of diseases like diabetic retinopathy long before they might be caught by traditional methods. This technology is democratizing access to specialist-level diagnostics, enabling screening to be performed in primary care settings and reducing the burden on ophthalmologists. The efficiency and precision of AI are not just improving patient outcomes but also creating new operational efficiencies for healthcare systems. The real-world adoption of AI is accelerating in the advanced ophthalmology technology market. As of mid-2024, 198 AI-equipped cameras have been deployed across five U.S. health systems, covering a population of approximately 151,000 patients with diabetes. In the United States, three FDA-approved AI algorithms for diabetic retinopathy screening were available as of 2025. The clinical uptake is evident in reimbursement data, with more than 15,000 Medicare claims filed for AI diabetic retinopathy screening algorithms since 2022. The efficacy of these systems was proven in a clinical trial involving 900 patients, which led to FDA approval for one AI eye exam system. The speed of these platforms is a key advantage; scans using the AEYE-DS diabetic retinopathy algorithm are designed to produce actionable results in under 60 seconds. Surgical Laser Precision and Speed Setting New Benchmarks for Ophthalmic Procedures Modern excimer and femtosecond lasers are the technological cornerstones of refractive and cataract surgery, and continuous innovation is pushing the boundaries of what is possible in the advanced ophthalmology technology market. Today's surgical laser platforms offer unparalleled precision, speed, and safety, enabling surgeons to perform highly customized and predictable procedures. Advancements in eye-tracking technology, laser pulse frequency, and treatment algorithms are leading to better visual outcomes, faster recovery times, and an enhanced patient experience. These technological leaps are critical for meeting the high expectations of patients seeking freedom from corrective eyewear and are a major factor in the continued growth of the refractive surgery market. The Bausch + Lomb TENEO Excimer Laser Platform exemplifies this cutting-edge technology with its impressive performance metrics. The platform boasts an exceptionally fast ablation time of approximately 1.2 seconds per diopter, minimizing procedure time and improving patient comfort. Supporting this speed is an advanced eye-tracker that operates at an incredible 1,740 Hz, ensuring the laser remains perfectly centered on the eye even with involuntary movements. The TENEO laser itself operates at a high speed of 500 Hz, allowing for swift and highly precise corneal tissue ablation. These specific, quantifiable advancements are what define the leading edge of the advanced ophthalmology technology market, delivering tangible benefits to both surgeons and patients. Customize the Data Scope to Match Your Objectives: Strategic Private Equity Investment and Remote Care Reshape Ophthalmic Service Delivery The business landscape of ophthalmology is being actively reshaped by two powerful forces: strategic investment from private equity and the rise of remote care models. Private equity firms are increasingly drawn to the sector's stable growth and opportunities for consolidation, leading to a wave of practice acquisitions. This trend is creating larger, more efficient practice groups with greater resources for technology adoption. In parallel, tele-ophthalmology platforms are gaining traction, leveraging technology to conduct remote eye exams and consultations. This remote care model is expanding access to services, particularly in underserved areas, and creating new, flexible models for delivering eye care. The impact of private equity is significant in the advanced ophthalmology technology market, with over 330 private equity-backed physician practice management (PPM) transactions recorded in ophthalmology over the last five years. This consolidation trend is fundamentally changing the structure of service delivery in the market. Simultaneously, the telehealth revolution is making its mark. The remote examination platform from DigitalOptometrics, for instance, has already conducted over 2 million remote exams. This number highlights a clear and growing acceptance of remote technologies by both patients and providers, signaling a permanent shift in how ophthalmic services can be delivered and scaled. Global Advanced Ophthalmology Technology Market Major Players: Alcon Allergan Bausch + Lomb Carl Zeiss Meditec EssilorLuxottica Heidelberg Engineering HOYA Johnson Johnson Vision NIDEK CO., LTD Novartis Ophthotech Corporation Regeneron Pharmaceuticals, Inc. Roche Samsung Topcon Other Prominent Players Key Market Segmentation: By Type Diagnostic Therapeutic By End Use Hospitals Ambulatory Surgical Centers (ASCs) Ophthalmic Clinics Others By Region North America Europe Asia Pacific Middle East & Africa South America Explore the Report Before You Buy – Book a Walkthrough: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
43 minutes ago
- Boston Globe
R.I.'s first Latina mayor won't run for lieutenant governor
On Tuesday morning, Rivera told the Globe she has decided against running for the post next year. 'After lots of reflection, I know where I'm meant to be. My heart is in Central Falls,' Rivera said. 'My focus is on the important work we've started here — like taking back local control of our schools, opening our historic new high school, expanding housing opportunities, growing our new business center to support local entrepreneurs, and building out the Conant Thread district around our new train station." Get Rhode Map A weekday briefing from veteran Rhode Island reporters, focused on the things that matter most in the Ocean State. Enter Email Sign Up She also cited plans for a community resource center and redevelopment of the former Osram Sylvania site. Advertisement 'We've made great progress, but there is still so much more to do,' Rivera said. 'I plan to see this work through and give my full attention to the people of Central Falls.' Rivera, 48, was Since taking office, Rivera has focused on replacing the city's Advertisement Rivera has $54,983 in her campaign account, and would have been considered a viable contender in the lieutenant governor's race. Matos, a Providence Democrat, is running for reelection, and former state Senator Cynthia Coyne has already A number of other people are considering jumping into the race, including Providence City Council member Edward Fitzpatrick can be reached at
Yahoo
2 hours ago
- Yahoo
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@ For updates, follow us on Twitter. Day 1August 20, 2025 8:45Virtual Lobby for the Conference. If you already registered, go back to the registration link and click 'Already registered' and enter your email. 9:00Introduction 9:05 – 9:35Immuron Limited (NASDAQ: IMRN)Keynote speaker: Steve Lydeamore, CEO 9:40 – 10:10Nutriband, Inc. (NASDAQ: NTRB)Keynote speaker: Serguei Melnik, Founder and President 10:50 – 11: Inc. (OTCQB: MGSTF) (CSE: METG)Keynote speaker: Colin Keddy, President 11:25 – 11:55Kelly+Partners (OTCQX: KPGHF) (ASX: KPG)Keynote speaker: Brett Kelly, Founder, Executive Chairman & CEO 12:35 – 1:05Journey Medical Corporation (NASDAQ: DERM)Keynote speaker: Claude Maraoui - Founder, President, CEO & Director 1:10 – 1:4022nd Century Group, Inc. (NASDAQ: XXII)Keynote speaker: Lawrence D. Firestone, Chairman & CEO 1:45 – 2:15Regen BioPharma Inc. (OTC Pink: RGBP)Keynote speakers: David Koos, President / CEO, & Harry M. Lander, Ph.D. Senior Scientific Consultant 2:20 – 2:50Clene Inc., (NASDAQ: CLNN)Keynote speakers: Rob Etherington, President / CEO 2:55 – 3:05Jaguar Health, Inc. (NASDAQ: JAGX)Keynote speaker: Lisa A. Conte, Founder, CEO, President & Director 3:10 – 3:20HeartSciences, Inc. (NASDAQ: HSCS) Keynote speaker: Andrew Simpson, President / CEO Postponed to September 24Adverum Biotechnologies (NASDAQ: ADVM) Keynote speaker: Jason Awe, PhD, MBA, Corporate Communications & IR 3:40 – 3:50GeoVax Labs, Inc. (NASDAQ: GOVX)Keynote speakers: David Dodd, Chairman, President / CEO 3:55 – 4:05BitFuFu Inc. (NASDAQ: FUFU)Keynote speaker: Charley Brady, VP Investor Relations 4:10 – 4:20Impact Minerals Limited, (ASX: IPT)Keynote speaker: Dr. Mike Jones, Managing Director 4:25 – 4:35Zyppah, a Private CompanyKeynote speaker: Dr. Jonathan Greenburg, founder and owner, & Larry Biggs, CEO 4:40 – 4:50Ucore Rare Metals, Inc. (OTCQX: UURAF) (TSXV: UCU)Keynote speakers: Pat Ryan, CEO ____________________ Day 2August 21, 2025 8:45Virtual Lobby for the Conference. If you already registered, go back to the registration link and click 'Already registered' and enter your email. 9:00Introduction 9:05 – 9:35Eshallgo, Inc. (NASDAQ: EHGO)Keynote speakers: Johnny Wu, President 10:15 – 10:45Terra Clean Energy (OTCQB: TCEFF) (CSE: TCEC)Keynote speaker: Greg Cameron, CEO 10:50 – 11:20Grove Collaborative Holdings, Inc. (NYSE: GROV)Keynote speakers: Jeff Yurcisin, CEO & Tom Siragusa, Interim CEO 11:25 – 11:55Phoenix Energy Services Corp., (OTCQB: PHXHF) (TSE: PHX)Keynote speaker: Mike Buker, President and CEO 12:00 – 12:30Vista Gold Corp. (NYSE American: VGZ) (TSX: VGZ) Keynote speaker: Frederick Earnest, CEO 12:35 – 1:05Eloro Resources, Ltd. (OTCQX: ELRRF) (TSX: ELO) Keynote speakers: Chris Holden – VP Corporate Development 1:10 – 1:40Kobo Resources, Inc. (OTCQB: KBRIF) (TSXV: KRI)Keynote speakers: Edouard Gosselin, Director, CEO and Corporate Secretary & Paul Sarjeant, Director, President and COO 1:45 – 2:15Puma Exploration Inc. (TSXV: PUMA) (OTCQB: PUMXF)Marcel Robillard, CEO & President 2:20 – 2:50U.S. Energy Corporation (NASDAQ: USEG)Keynote speaker: Ryan Smith, President, CEO & Director 2:55 – 3:05Highland Copper Company Inc. (OTCQB: HDRSF) (TSXV: HI)Keynote speaker: Barry O'Shea, CEO 3:10 - 3:20Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) Keynote speaker: Mark D. Gordon, Chairman & CEO 3:25 – 3:35C3 Metals Inc. (TSXV: CCCM) (OTCQB: CUAUF)Keynote speaker: Daniel A. Symons, President, CEO & Director 3:40 – 3:50Lahontan Gold Corp. (TSXV: LG) (OTCQB: LGCXF) Keynote speaker: Kimberly Ann, President / CEO 3:55 – 4:05Opawica Explorations Inc. (OTCQB: OPWEF) (TSXV: OPW)Keynote speaker: Blake Morgan, President / CEO 4:10 – 4:20Vizsla Royalties Corp. (TSXV: VROY) (OTCQB: VROYF)Keynote speaker: Michael N. Pettingell, President and CEO 4:25 – 4:35Star Gold Corp. (OTCQB: SRGZ)Keynote speaker: Lindsay E. Gorrill, Chairman & CEO 4:40 – 4:50NCS Multistage Holdings, Inc. (NASDAQ: NCSM)Keynote speaker: Ryan Hummer, CEO & Director Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@ Replays: Subscribe to our YouTube Channel. About Founded in 2009, Emerging quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community. About the Emerging Growth Conference The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner. All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on If you believe or know of a company that might fit our audience, contact us here. Thank you for your interest in our conference, and we look forward to your participation in future conferences. Contact: Emerging Growth Phone: 1-305-330-1985Email: Conference@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
